Counter-balancing X-linked hypofunction by hyperfunction ameliorates disease features in a model of Rett syndrome: implications for genetic therapies

Christopher M McGraw,Sirena Soriano,Hao Shuang,Daniel R Connolly,Ali Chahrour,Zhenyu Wu,Agnes J Liang,Yaling Sun,Jianrong Tang,Rodney C Samaco

DOI: https://doi.org/10.1101/2024.01.18.576265

2024-01-20

Abstract:Treating monogenic neurodevelopmental disorders remains challenging and mostly symptomatic. X-linked disorders affecting women such as the postnatal neurodevelopmental disorder Rett syndrome (caused by mutations in the gene ) have additional challenges due to dosage sensitivity and to cellular mosaicism caused by random X-chromosome inactivation. An approach to augment expression from wild-type cells in RTT may be feasible and simpler than gene replacement but has never been tested due to known toxicity of over-expression, as evidenced by the distinct neurological condition known as Duplication Syndrome. Here, using genetic techniques, we find that “counter-balancing” -null cells in female -null/+ mice by a complementary population of cells harboring an X-linked transgene associated with 3X normal levels of leads to normalization of multiple whole animal phenotypic outcomes without noticeable toxicity. In addition, LFP recordings demonstrate that counter-balancing loss-of-function improves select within-region and between-region abnormalities. By comparing the counter-balance approach with an approach based on cell autonomous restoration of MeCP2 using an autosomal transgene expressing 2X normal levels of in all cells (mimicking gene replacement), we identify neurobehavioral and electrographic features best suited for preclinical biomarkers of a therapeutic response to cell autonomous versus non-cell autonomous correction. Notably, these proof-of-concept findings demonstrate how non-cell autonomous suppression of MeCP2 deficiency by boosting overall wild-type MeCP2 levels may be a viable disease-modifying therapy for RTT, with potential implications for genetic-based therapies of monogenic X-linked disorders.

Neuroscience

What problem does this paper attempt to address?

The problem this paper attempts to address is the therapeutic challenge of treating Rett syndrome (RTT). Rett syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene on the X chromosome, primarily affecting females. Due to the dosage sensitivity of the MECP2 gene and cellular mosaicism resulting from random X-chromosome inactivation, treating this disease is particularly challenging. The paper proposes a novel strategy to "balance" the loss of MECP2 function by introducing a complementary population of cells that overexpress MECP2 in cells with MECP2 loss-of-function (LoF), thereby improving the symptoms of Rett syndrome.

Specifically, the research team utilized genetic techniques in female MECP2 gene knockout mice (Mecp2-null/+) by introducing an X-linked human MECP2 transgene (hMECP2-TG3) that overexpresses MECP2 at 3 times the normal level, achieving a "reverse balance" of MECP2 function loss. The study found that this "reverse balance" strategy not only lacked significant toxicity but also significantly improved various whole-animal phenotypic outcomes, including behavioral, physiological, and electrophysiological abnormalities. Additionally, by comparing the "reverse balance" method with another approach based on cell-autonomous restoration of MECP2 (using an autosomal transgene expressing MECP2 at 2 times the normal level), the researchers identified neurobehavioral and electroencephalographic features that best serve as preclinical biomarkers. These features can distinguish the effects of cell-autonomous versus non-cell-autonomous correction.

In summary, this study demonstrates that non-cell-autonomous suppression of MECP2 function loss by increasing overall wild-type MECP2 levels may be a viable therapeutic approach for Rett syndrome. This has potential implications for gene-based therapies for monogenic X-linked disorders.